TerSera | News & Insights

News & insights

Discover the latest from TerSera

TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE
- Press Release
- |
- March 10, 2026
ESTEVE to acquire TerSera Therapeutics’ Infusion Specialty Therapies Business Unit, Expanding U.S. presence
- Press Release
- |
- January 13, 2026
TerSera Therapeutics to Present Real-World Data on Intrathecal Ziconotide (PRIALT®) Prescription Patterns at ASPN 2025
- Press Release
- |
- July 18, 2025
TerSera® Receives National Recognition as a 2025 USA Today Top Workplace
- Press Release
- |
- May 20, 2025
TerSera® Presents New Real-World Evidence on Treatment Outcomes of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
- Press Release
- |
- December 12, 2024
MacroGenics Enters into Agreement with TerSera Therapeutics for the Sale of MARGENZA®
- Press Release
- |
- October 22, 2024
TerSera® Presents Real-World Evidence on Treatment Patterns of Goserelin (ZOLADEX®) in Women with Breast Cancer at the 2024 American Society of Clinical Oncology (ASCO) Quality Care Symposium
- Press Release
- |
- October 2, 2024
TerSera Therapeutics LLC Announces that the 2024 Polyanalgesic Consensus Conference (PACC) Guidelines issued updated guidance for administering PRIALT
- Press Release
- |
- July 23, 2024
Health Canada approves ZOLADEX® LA for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women.
- Press Release
- |
- May 7th, 2024
Goserelin Dosing Options Included in the National Comprehensive Cancer Network® (NCCN) Breast Cancer Guidelines
- Press Release
- |
- February 5, 2024

Unless otherwise specified, all company and product names appearing in this Website are trademarks owned by or licensed to TerSera Therapeutics LLC, its subsidiaries or affiliates. No use of any TerSera trademark, trade name, or trade dress in this Website may be made without the prior written authorization of TerSera, except to identify the product or services of the company.